Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | MER proto-oncogene, tyrosine kinase | Starlite/ChEMBL | References |
Homo sapiens | AXL receptor tyrosine kinase | Starlite/ChEMBL | References |
Homo sapiens | TYRO3 protein tyrosine kinase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma japonicum | IPR008957,Fibronectin, type III-like fold,domain-containing | Get druggable targets OG5_132328 | All targets in OG5_132328 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0017 | 0.1369 | 0.2302 |
Onchocerca volvulus | 0.0017 | 0.1369 | 0.5 | |
Loa Loa (eye worm) | CAMK/MLCK protein kinase | 0.0021 | 0.3491 | 0.5988 |
Echinococcus granulosus | roundabout 2 | 0.0021 | 0.3491 | 0.3491 |
Echinococcus multilocularis | receptor type tyrosine protein phosphatase | 0.0021 | 0.3491 | 0.3491 |
Schistosoma mansoni | nephrin | 0.0028 | 0.7878 | 0.9933 |
Loa Loa (eye worm) | projectin | 0.0017 | 0.1369 | 0.2302 |
Loa Loa (eye worm) | TK/KIN16 protein kinase | 0.0019 | 0.2361 | 0.4024 |
Brugia malayi | Immunoglobulin I-set domain containing protein | 0.0019 | 0.2361 | 0.2237 |
Brugia malayi | Immunoglobulin I-set domain containing protein | 0.0017 | 0.1413 | 0.01 |
Brugia malayi | Immunoglobulin I-set domain containing protein | 0.0021 | 0.3491 | 0.4789 |
Schistosoma mansoni | receptor tyrosine phosphatase type r2a | 0.0021 | 0.3491 | 0.3238 |
Echinococcus multilocularis | transfer RNA-Phe | 0.0017 | 0.1369 | 0.1369 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.58 | 1 |
Echinococcus multilocularis | insulin growth factor 1 receptor beta | 0.0018 | 0.1608 | 0.1608 |
Schistosoma mansoni | cell adhesion molecule | 0.0021 | 0.3491 | 0.3238 |
Echinococcus granulosus | titin | 0.0017 | 0.1369 | 0.1369 |
Echinococcus granulosus | titin | 0.0017 | 0.1369 | 0.1369 |
Loa Loa (eye worm) | immunoglobulin I-set domain-containing protein | 0.0017 | 0.1369 | 0.2302 |
Echinococcus granulosus | contactin | 0.0021 | 0.3491 | 0.3491 |
Brugia malayi | Fibronectin type III domain containing protein | 0.0025 | 0.58 | 1 |
Schistosoma mansoni | cell adhesion molecule | 0.0028 | 0.7922 | 1 |
Echinococcus multilocularis | roundabout 2 | 0.0021 | 0.3491 | 0.3491 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.58 | 1 |
Brugia malayi | Immunoglobulin I-set domain containing protein | 0.0025 | 0.58 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0018 | 0.2122 | 0.361 |
Echinococcus granulosus | Down syndrome cell adhesion molecule | 0.0017 | 0.1413 | 0.1413 |
Echinococcus multilocularis | roundabout 2 | 0.0032 | 1 | 1 |
Schistosoma mansoni | cell adhesion molecule | 0.0021 | 0.3491 | 0.3238 |
Loa Loa (eye worm) | immunoglobulin I-set domain-containing protein | 0.0021 | 0.3491 | 0.5988 |
Loa Loa (eye worm) | immunoglobulin I-set domain-containing protein | 0.0017 | 0.1413 | 0.2379 |
Echinococcus multilocularis | receptor type tyrosine protein phosphatase F | 0.0021 | 0.3491 | 0.3491 |
Loa Loa (eye worm) | hypothetical protein | 0.0018 | 0.2122 | 0.361 |
Echinococcus granulosus | insulin growth factor 1 receptor beta | 0.0018 | 0.1608 | 0.1608 |
Echinococcus multilocularis | roundabout 2 | 0.0021 | 0.3491 | 0.3491 |
Brugia malayi | Immunoglobulin I-set domain containing protein | 0.0021 | 0.3491 | 0.4789 |
Schistosoma mansoni | ephrin receptor | 0.0018 | 0.1608 | 0.0364 |
Echinococcus granulosus | neurotracting:lsamp:neurotrimin:obcam | 0.0015 | 0.0044 | 0.0044 |
Echinococcus granulosus | receptor type tyrosine protein phosphatase | 0.0021 | 0.3491 | 0.3491 |
Onchocerca volvulus | 0.0017 | 0.1369 | 0.5 | |
Brugia malayi | hypothetical protein | 0.0025 | 0.58 | 1 |
Loa Loa (eye worm) | CAMK/MLCK protein kinase | 0.0017 | 0.1369 | 0.2302 |
Echinococcus granulosus | neuroglian | 0.0021 | 0.3491 | 0.3491 |
Brugia malayi | Immunoglobulin I-set domain containing protein | 0.0021 | 0.3491 | 0.4789 |
Onchocerca volvulus | 0.0017 | 0.1369 | 0.5 | |
Echinococcus multilocularis | Down syndrome cell adhesion molecule | 0.0017 | 0.1413 | 0.1413 |
Echinococcus granulosus | nephrin | 0.0017 | 0.1369 | 0.1369 |
Echinococcus granulosus | roundabout 2 | 0.0021 | 0.3491 | 0.3491 |
Loa Loa (eye worm) | hypothetical protein | 0.0021 | 0.3491 | 0.5988 |
Schistosoma mansoni | neuroglian | 0.0021 | 0.3491 | 0.3238 |
Echinococcus multilocularis | titin | 0.0017 | 0.1369 | 0.1369 |
Loa Loa (eye worm) | immunoglobulin I-set domain-containing protein | 0.0017 | 0.1369 | 0.2302 |
Schistosoma mansoni | nephrin | 0.0021 | 0.3491 | 0.3238 |
Loa Loa (eye worm) | CAMK protein kinase | 0.0017 | 0.1369 | 0.2302 |
Loa Loa (eye worm) | immunoglobulin I-set domain-containing protein | 0.0017 | 0.1369 | 0.2302 |
Echinococcus multilocularis | receptor type tyrosine protein phosphatase | 0.0021 | 0.3491 | 0.3491 |
Echinococcus granulosus | receptor type tyrosine protein phosphatase | 0.0017 | 0.1369 | 0.1369 |
Loa Loa (eye worm) | hypothetical protein | 0.0017 | 0.1369 | 0.2302 |
Echinococcus multilocularis | contactin neuroglian septate junction protein | 0.0021 | 0.3491 | 0.3491 |
Echinococcus multilocularis | neuroglian | 0.0021 | 0.3491 | 0.3491 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.58 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 160 nM | Inhibition of Mer kinase (unknown origin) using 5-FAM-EFPIYDFLPAKKK-CONH2 as substrate after 180 mins by microfluidic capillary electrophoresis assay | ChEMBL. | 24195762 |
IC50 (binding) | = 1370 nM | Inhibition of Tyro-3 kinase (unknown origin) using 5-FAM-EFPIYDFLPAKKK-CONH2 as substrate after 180 mins by microfluidic capillary electrophoresis assay | ChEMBL. | 24195762 |
IC50 (binding) | = 3700 nM | Inhibition of Axl kinase (unknown origin) using 5-FAM-KKKKEEIYFFF-CONH2 as substrate after 180 mins by microfluidic capillary electrophoresis assay | ChEMBL. | 24195762 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.